Andere Sprachen Royalty Pharma plc

Aktien

A2P62D

GB00BMVP7Y09

RPRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
28.11 ^USD	+0.46%		+0.79%	+0.07%

17.04.	Royalty Pharma plc beschließt Dividende für das zweite Quartal 2024, zahlbar am 14. Juni 2024	CI
09.04.	ROYALTY PHARMA PLC : Bewertung von Morgan Stanley zum Kaufen erhalten	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fitch Affirms Royalty Pharma plc at 'BBB-'; Outlook Stable	22.04.
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024	19.04.
Royalty Pharma Maintains Quarterly Dividend at $0.21 per Share, Payable June 14 to Shareholders of Record May 17	17.04.
Royalty Pharma Declares Second Quarter 2024 Dividend	17.04.
Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024	17.04.
Royalty Pharma : EEO-1 2023 Consolidated Report	03.04.
Royalty Pharma : TD Cowen Health Care Conference Transcript	07.03.
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference	28.02.
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference	28.02.
Tranche Update on Royalty Pharma plc's Equity Buyback Plan announced on March 28, 2023.	15.02.
Royalty Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	15.02.
Royalty Pharma Swings to Q4 Net Income, Revenue Increases	15.02.
Royalty Pharma: Q4 Earnings Snapshot	15.02.
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15.02.
Earnings Flash (RPRX) ROYALTY PHARMA Reports Q4 Revenue $596M, vs. Street Est of $674.5M	15.02.
Royalty Pharma Reports Q4 and Full Year 2023 Results	15.02.
Royalty Pharma Reports Q4 and Full Year 2023 Results	15.02.
Novartis will Morphosys schlucken - Zugriff auf Hoffnungsträger	06.02.
Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG for ?2.7 billion.	05.02.
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024	30.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Royalty Pharma plc

Aktien

A2P62D

GB00BMVP7Y09

RPRX

Andere Sprachen

Filter